Literature DB >> 9096686

Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells.

M Towatari1, H Iida, M Tanimoto, H Iwata, M Hamaguchi, H Saito.   

Abstract

Mitogen-activated protein (MAP) kinase appears to be one of the key regulators of cell proliferation and differentiation. Very little, however, has been revealed as to how MAP kinase is involved in leukemogenesis. We have studied the activation of the MAP kinase pathway in 100 human primary leukemia cells including 73 acute myelogenous leukemias (AMLs). Forty acute leukemia samples (40% of the total), including 37 AML samples (51% of AML), showed activation of MAP kinase as revealed by the mobility shift of the phosphorylated form of the protein and by in vitro kinase assay. This activation was correlated with MAP kinase kinase activity in these cells. In contrast, none of 14 chronic myelogenous leukemia samples showed the activation of MAP kinase. These results suggest that the MAP kinase pathway is constitutively activated in a subset of primary acute leukemias, and thus indicate the possible role of the constitutively activated MAP kinase in leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9096686     DOI: 10.1038/sj.leu.2400617

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  31 in total

1.  Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells.

Authors:  M Fiegl; I Samudio; Z Mnjoyan; B Korchin; H Fritsche; M Andreeff
Journal:  Leukemia       Date:  2010-05-27       Impact factor: 11.528

2.  Central role of protein kinase Cepsilon in constitutive activation of ERK1/2 and Rac1 in the malignant cells of hairy cell leukemia.

Authors:  Joseph R Slupsky; Aura S Kamiguti; Robert J Harris; John C Cawley; Mirko Zuzel
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 3.  Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis.

Authors:  Daniel E Johnson
Journal:  Adv Enzyme Regul       Date:  2007-11-19

4.  Cordycepin induces cell cycle arrest and apoptosis by inducing DNA damage and up-regulation of p53 in Leukemia cells.

Authors:  Yuanhong Liao; Jianya Ling; Guoying Zhang; Fengjun Liu; Shengce Tao; Zeguang Han; Saijuan Chen; Zhu Chen; Huangying Le
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity.

Authors:  Sarvesh Jajoo; Debashree Mukherjea; Kounosuke Watabe; Vickram Ramkumar
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

6.  The activity of extracellular signal-regulated kinase is required during G2/M phase before metaphase-anaphase transition in synchronized leukemia cell lines.

Authors:  Katarina Matkovic; Vesna Lukinovic-Skudar; Hrvoje Banfic; Dora Visnjic
Journal:  Int J Hematol       Date:  2009-01-17       Impact factor: 2.490

Review 7.  Exploiting cellular pathways to develop new treatment strategies for AML.

Authors:  Amir T Fathi; Steven Grant; Judith E Karp
Journal:  Cancer Treat Rev       Date:  2010-01-06       Impact factor: 12.111

Review 8.  Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

Authors:  Giampaolo Tortora; Roberto Bianco; Gennaro Daniele; Fortunato Ciardiello; James A McCubrey; Maria Rosaria Ricciardi; Ludovica Ciuffreda; Francesco Cognetti; Agostino Tafuri; Michele Milella
Journal:  Drug Resist Updat       Date:  2007-05-07       Impact factor: 18.500

9.  Nucleoporins nup98 and nup214 participate in nuclear export of human immunodeficiency virus type 1 Rev.

Authors:  A S Zolotukhin; B K Felber
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.

Authors:  Andrea E Wahner Hendrickson; Paul Haluska; Paula A Schneider; David A Loegering; Kevin L Peterson; Ricardo Attar; B Douglas Smith; Charles Erlichman; Marco Gottardis; Judith E Karp; Joan M Carboni; Scott H Kaufmann
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.